Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

Biotechnology

Health Care

Entact Bio

Victoria Richon

Stefanie Schalm

Victor Serebrov

Simon Bushell

Paul Perkins

Owen Smith

Elma Kadic

Bob Soh

The Biological Sciences Research team at Entact Bio focuses on advancing the understanding of deubiquitinase (DUB) biology and its implications for protein function in disease. Utilizing their expertise in chemical biology and small-molecule drug development, the team collaborates on the design and optimization of enhancement-targeting chimeric (ENTAC) medicines through the proprietary EncompassTM platform, ultimately driving the preclinical development of innovative therapeutic options.

Biological Sciences Research

Leadership Team

Research and Development

Biological Sciences Research

About

Team members

Other teams at Entact Bio

Leadership Team

Research and Development